SOURCE: Vicor Technologies, Inc.

Vicor Technologies, Inc.

August 07, 2009 08:30 ET

Trial Findings for Vicor Technologies PD2i Vital Sign Diagnostic to Be Presented at the ATACCC 2009 Conference

BOCA RATON, FL--(Marketwire - August 7, 2009) - David Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Andriy Batchinsky, MD, a researcher with the U.S. Army Institute of Surgical Research (USAISR), will present findings from trials of Vicor's PD2i VS (Vital Sign) that have been performed under a collaborative agreement between Vicor and the USAISR at Smart Monitoring 2009 and the ATACCC 2009 Conference on August 10-12, 2009 in St. Petersburg Beach, Florida. Smart Monitoring, which immediately precedes the ATACCC Conference, is a forum for open discussions focused on vital signs monitoring for combat casualty care. The ATACCC (Advanced Technology Applications for Combat Casualty Care) Conference is the premier scientific meeting of the Department of Defense (DOD). Vicor is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of life saving intervention.

Dr. Batchinsky will make two presentations. The first -- "Toward Automated Detection of Life-threatening Injury Using Comprehensive Assessment of the Electrocardiogram" -- will be presented at the Smart Monitoring 2009 Conference during a panel discussion entitled, "New Vital Signs, Predictive Variables and Indices," on Sunday, August 9. The second -- "Does Heart Rate Complexity Add to Traditional Vital Signs for Trauma Patient Triage?" -- will be presented at the ATACCC 2009 Conference on Tuesday, August 11. Both presentations will a) detail the use of Vicor's PD2i VS as a new vital sign diagnostic that more accurately risk stratifies trauma severity and the probability of survival in the critically injured, and b) provide a review of findings from trials conducted under the Collaborative Research and Development Agreement (CRADA) between Vicor and the USAISR begun in January 2008.

"We're extremely pleased and honored to have our PD2i VS diagnostic presented at Smart Monitoring 2009 and the ATACCC 2009 Conference by Dr. Batchinsky, who has been actively involved in all of the clinical trials of the PD2i VS conducted under the CRADA," stated Mr. Fater. "As we steadily advance commercialization of our PD2i diagnostics, visibility at prestigious conferences such as these enhances our opportunity to explore new strategic relationships and collaborative efforts that may enable us to identify new applications for the PD2i," he continued. "Additional information about the PD2i VS and trials demonstrating its effectiveness to risk stratify trauma severity -- along with information about our other PD2i diagnostics -- may be found at our new website:," Mr. Fater concluded.

Sponsored by the Resuscitation Research Laboratory of the University of Texas Medical Branch, Smart Monitoring addresses the need for new technologies requiring innovation from government, academia, and industry by providing a forum for communication between industry representatives and expert medical caregivers.

The ATACCC addresses critical advances in trauma medicine and the unique medical needs of the war fighter, with a focus on the growing and changing operational issues and identifies technologies available today and in the future that can be used to meet these increasingly complex goals. Additional information about the ATACCC 2009 Conference may be found at

About Vicor Technologies, Inc.

Vicor Technologies is a development-stage biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i.) The PD2i is a deterministic, non-linear measure that analyzes electrophysiological potentials to predict future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i algorithm. The PD2i Analyzer, which has FDA 510(k) marketing clearance, measures heart rate variability and will be commencing a clinical trial to determine its efficacy to detect the presence of diabetic autonomic neuropathy (DAN). The PD2i VS (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (, risk stratifies combat and civilian trauma victims. The PD2i CA (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of suffering sudden cardiac death.

Vicor anticipates additional applications employing the PD2i to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at

The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements

Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to obtain FDA approval of the PD2i VS for military and civilian applications and the PD2i Cardiac Analyzer, our ability continue to receive financing sufficient to continue operations and complete the critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 09-11

Contact Information